
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health is experiencing a temporary decline in its stock due to raised expectations for its Home and Women's Health division and a weaker 2Q EBITDA forecast. However, management is confident in a potential 2H ramp up, and the company's 2026 guidance has been reduced marginally but still expects strong revenue and earnings growth. It is difficult for the company to maintain this level of growth without competitive exits or procurement benefits in other drug categories, leading to potential downside risk.
Bears say
Option Care Health is facing significant challenges such as unexpected headwinds in certain therapies, weaker-than-expected performance in lower-margin therapies, and declines in revenue and cash generation as reflected in its recent mixed-bag first quarter results and updated financial guidance. The company's 2026 financial targets may be perceived as aggressive by investors with its assumption of significant growth in the second half of 2026, leading to a significant share price decline. It is also important to note that materiality can vary between sectors and over time, making it difficult to accurately assess the company's ESG performance.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares